KLK3 and Familial prostate cancer: The European Randomized Study of Screening for Prostate Cancer (ERSPC) trial reported that PSA screening was associated with a 20% relative reduction in prostate cancer mortality at a median follow-up of 9 years, resulting in reduction of about 7 prostate cancer deaths per 10,000 men screened [90].